These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Tumor necrosis factor and AIDS--the mechanism of development of AIDS]. Kobayashi N Tanpakushitsu Kakusan Koso; 1989 Nov; 34(14):1904-10. PubMed ID: 2594987 [No Abstract] [Full Text] [Related]
43. Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. Warzocha K; Bienvenu J; Coiffier B; Salles G Eur Cytokine Netw; 1995; 6(2):83-96. PubMed ID: 7578992 [TBL] [Abstract][Full Text] [Related]
44. [Tumor necrosis factor alpha (cachectin). Biological properties and role in physiopathology]. Blay JY; Chouaib S Presse Med; 1989 May; 18(19):975-9. PubMed ID: 2525723 [TBL] [Abstract][Full Text] [Related]
45. [In vitro studies of anemia accompanying a chronic inflammatory processes and neoplasms. Effect of cachectin (TNF-alpha) and lymphotoxin (TNF-beta) on human erythropoiesis]. Ratajczak MZ; Ratajczak J Pol Tyg Lek; 1994 Mar 21-28; 49(12-13):280-3. PubMed ID: 7808952 [TBL] [Abstract][Full Text] [Related]
47. Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. Gibbons DL; Rowe M; Cope AP; Feldmann M; Brennan FM Eur J Immunol; 1994 Aug; 24(8):1879-85. PubMed ID: 8056047 [TBL] [Abstract][Full Text] [Related]
48. Cachectin: its impact on metabolism and nutritional status. Moldawer LL; Lowry SF; Cerami A Annu Rev Nutr; 1988; 8():585-609. PubMed ID: 3060179 [No Abstract] [Full Text] [Related]
49. Tumor necrosis factors: developments during the last decade. Aggarwal BB; Natarajan K Eur Cytokine Netw; 1996; 7(2):93-124. PubMed ID: 8688493 [No Abstract] [Full Text] [Related]
50. [Tumor necrosis factor alpha and beta (TNF-alpha and -beta) in pathogenesis of rheumatoid arthritis]. Yamamura M Nihon Rinsho; 2005 Jan; 63 Suppl 1():145-52. PubMed ID: 15799335 [No Abstract] [Full Text] [Related]
51. Simultaneous production of tumor necrosis factor-alpha and lymphotoxin by normal T cells after induction with IL-2 and anti-T3. Steffen M; Ottmann OG; Moore MA J Immunol; 1988 Apr; 140(8):2621-4. PubMed ID: 3258616 [TBL] [Abstract][Full Text] [Related]
52. Tumor necrosis factor alpha and lymphotoxin production in Hodgkin's disease. Kretschmer C; Jones DB; Morrison K; Schlüter C; Feist W; Ulmer AJ; Arnoldi J; Matthes J; Diamantstein T; Flad HD Am J Pathol; 1990 Aug; 137(2):341-51. PubMed ID: 2386200 [TBL] [Abstract][Full Text] [Related]
53. Tumour necrosis factor/cachectin: biology and relevance to disease. Das UN J Assoc Physicians India; 1991 Feb; 39(2):201-4. PubMed ID: 1885487 [TBL] [Abstract][Full Text] [Related]
54. Cachectin/tumor necrosis factor and interleukin-1 show different modes of combined effect on lipoprotein lipase activity and intracellular lipolysis in 3T3-L1 cells. Ogawa H; Nielsen S; Kawakami M Biochim Biophys Acta; 1989 Jun; 1003(2):131-5. PubMed ID: 2786429 [TBL] [Abstract][Full Text] [Related]
55. The tumor necrosis factor ligand and receptor families. Bazzoni F; Beutler B N Engl J Med; 1996 Jun; 334(26):1717-25. PubMed ID: 8637518 [No Abstract] [Full Text] [Related]
56. [TNF-alpha (cachectin) as a lymphokine regulator]. Tchórzewski H Acta Haematol Pol; 1994; 25(2 Suppl 1):56-61. PubMed ID: 8067208 [TBL] [Abstract][Full Text] [Related]
57. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. Fong Y; Tracey KJ; Moldawer LL; Hesse DG; Manogue KB; Kenney JS; Lee AT; Kuo GC; Allison AC; Lowry SF J Exp Med; 1989 Nov; 170(5):1627-33. PubMed ID: 2809510 [TBL] [Abstract][Full Text] [Related]
58. [Biosynthesis of alpha2-interferon and tumor necrosis factor at different stages of culturing]. Andreeva IS; Lebedev LR; Sinichkina SA; Puchkova LI; Pustoshilova NM Mol Gen Mikrobiol Virusol; 1996; (3):23-6. PubMed ID: 8999314 [TBL] [Abstract][Full Text] [Related]
59. Type I interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cell. Abu-Khabar KS; Armstrong JA; Ho M J Leukoc Biol; 1992 Aug; 52(2):165-72. PubMed ID: 1506772 [TBL] [Abstract][Full Text] [Related]
60. Membrane lymphotoxin is required for resistance to Theiler's virus infection. Lin X; Ma X; Rodriguez M; Feng X; Zoecklein L; Fu YX; Roos RP Int Immunol; 2003 Aug; 15(8):955-62. PubMed ID: 12882833 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]